CTLA4 and neoplasm: Both HPV-positive and HPV-negative tumours display a high level of immune checkpoint components, such as PD-1 and cytotoxic T-lymphocyte protein 4 (CTLA-4).105 A smaller benefit induced by immunotherapeutic treatments has been observed in females in comparison with males for different tumour types, including HNSCC.